+40 Senior Executives Joined the Atlas Portfolio, Including 10 CEOs

Jodie Morrison

CEO at Cadent Therapeutics

"In joining the Atlas portfolio and Cadent's talented team, I've had the opportunity to build an organization that will pave the way for new advances in neuroscience drug development."

"I decided to join Accent because of the amazing team and the opportunity to build a pipeline of novel oncology drugs focused on meaningful patient impact. To this end, the Atlas team has been incredibly thoughtful, helpful and supportive."

Rene Russo

CEO at Akrevia Therapeutics

"I chose to work with Atlas Venture as CEO of Akrevia - an exciting IO biotech in their portfolio - because of the commitment Atlas has to cutting edge science with the potential to be transformational for patients."

	ANDREA DIMELLA VP, Head of Talent
	SARAH GERRISH Executive Assistant
	JERNEJ GODEC, PhD Associate
	CHELSEA PLACE JOHNSON, PhD Senior Associate
	SHARON MORANI Director of Portfolio Operations

3 M&A Events totaling $2.8B in potential value

Royalty Pharma acquired Arteaus's Emgality Royalty

Spanning disease areas and modalities

Followed by >100 preclinical programs

5 Partnerships signed representing over $3B in potential deal value.

+100 Active job postings across the Atlas Portfolio

Atlas Venture Retreat

The 2019 Atlas Venture Retreat convened leaders in pharma and Atlas portfolio companies for several days of engaging content from industry experts like former FDA Commissioner Scott Gottlieb

Atlas Venture Annual Meeting

The 2019 Atlas Venture Annual Meeting featured founders of JB's Keys to DMD, JB Harvey and Beth Harvey to share their journey with Duchenne Muscular Dystrophy with the LP community

Science2Startup

The third annual Science2Startup will be held
May 6, 2020 - visit www.science2startup.com to learn more

Emerging Company Analyst Day

Our Emerging Company Analyst Days engaged a curated group of biotech analysts with Atlas portfolio companies

2019 Year in Review Presented by Bruce Booth
Role of VCs in the Biotech 4.0 Ecosystem Jason Rhodes joins Evercore ISI to discuss a range of biotech topics from a VC perspective
Venturing A Perspective On The Drug Pricing Debate LifeSciVC post by Bruce Booth
Just Because You Can Doesn't Mean You Should: Gene Therapy is Not the Solution to Every Problem Timmerman Report article by Alex Harding
Maybe It's Innate From the Trenches post by Samantha Truex, CEO of Quench Bio

Spanning disease areas and modalities

Followed by >100 preclinical programs

Atlas Venture Retreat

Atlas Venture Annual Meeting

Science2Startup

Emerging Company Analyst Day

2019 Year in Review

Role of VCs in the Biotech 4.0 Ecosystem

Venturing A Perspective On The Drug Pricing Debate

Just Because You Can Doesn't Mean You Should: Gene Therapy is Not the Solution to Every Problem

Maybe It's Innate